scholarly journals Ambiguity of Propranolol Side Effects in 100 Patients Treated for Infantile Hemangioma

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Danielle H ◽  
Dor L ◽  
Avraham L
Keyword(s):  
Side Effects ◽  
Infantile Hemangioma

scholarly journals Efficacy of propranolol in infantile hemangioma

2015 ◽  
Vol 47 (1-2) ◽  
pp. 32-35
Author(s):  
Mizanur Rahman ◽  
Md Tarikul Islam ◽  
Ratan Lal Dutta Banik ◽  
Choudhury Habibur Rasul
Keyword(s):  
Side Effects ◽  
Cosmetic Surgery ◽  
Low Dose ◽  
Relevant Literature ◽  
Infantile Hemangioma ◽  
Benign Tumors ◽  
Dose Oral ◽  
Oral Propranolol ◽  
Intralesional Steroids ◽  
Surgery Resection

Hemangiomas, are the most common benign tumors of infancy. Despite their selflimited course, infantile capillary hemangiomas can cause local complications e.g. pain, ulceration, bleeding etc. The usual treatments include oral/intralesional steroids, alpha interferon, cytotoxins, pulsed dye laser and cosmetic surgery resection. These treatments are not free of multiple complications and toxic side effects. We report our experience with the use of propranolol in 2 children with haemangiomas along with review of relevant literature. Both the hemangioma cases promptly responded to low-dose oral propranolol. DOI: http://dx.doi.org/10.3329/bmjk.v47i1-2.22561 Bang Med J (Khulna) 2014; 47 : 32-35

scholarly journals Propranolol for extensive hemangiomas of infancy: two case reports

2011 ◽  
Vol 10 (2) ◽  
pp. 173-176
Author(s):  
Luíza Helena dos Santos Cavaleiro ◽  
Fernanda de Oliveira Viana ◽  
Deborah Aben Athar Unger ◽  
Maraya de Jesus Semblano Bittencourt
Keyword(s):  
Side Effects ◽  
Large Volume ◽  
Rapid Growth ◽  
Case Reports ◽  
Therapeutic Option ◽  
Functional Limitation ◽  
Infantile Hemangioma ◽  
Benign Tumors ◽  
Systemic Glucocorticoids ◽  
Total Disappearance

Hemangiomas are the most common benign tumors of childhood. They show rapid growth, followed by a regression phase that culminates in the partial or total disappearance of the lesion. Therapeutic options should be evaluated for extensive cases. Systemic glucocorticoids are the therapy of choice; however, there are reports that propranolol offers better and faster results. We report two cases of large volume infantile hemangioma associated with functional limitation and aesthetic disfigurement, treated successfully with propranolol, a drug that comes as a therapeutic option providing satisfactory and maintained results, with few side effects.

scholarly journals Comparative study between intralesional Dexamethasone and oral Prednisolone in the treatment of Infantile Hemangioma

2015 ◽  
Vol 5 (1) ◽  
pp. 12-19
Author(s):  
Tahmina Akhter Chowdhury ◽  
Akbar Husain Bhuiyan ◽  
Mohammed Monjurul Hakim
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Color Change ◽  
Oral Prednisolone ◽  
Infantile Hemangioma ◽  
Excessive Weight ◽  
Oral Steroids ◽  
Group A ◽  
Group B ◽  
Age Range

Background: Infantile Hemangioma (IH) is one of the most common childhood neoplasm. Current treatments for children with endangering Infantile Hemangioma are limited, and include primarily oral corticosteroid which has many systemic adverse effects. Furthermore, approximately one third of IH does not respond to oral steroids, prompting active investigations for new treatments.Objective: To compare the efficacy, side effects, and influencing factors of oral Prednisolone and intralesional Dexamethasone (IL) in treatment of IH and thus to find out an effective, cheap and safe modality of treatment for this anomaly.Materials and Methods: This study was carried out on 48 patients of IH with the age range from 1 day to 12 years. Group A (n1=26) patients were treated by oral Prednisolone and group B (n2=22) patients were treated by IL Dexamethasone .Periorbital Hemangioma and IH >54 cubic centimeter were excluded. Therapeutic response of Prednisolone and Dexamethasone was graded as excellent, good, poor and no response. We monitored volume of the lesion and its color change to evaluate the response to treatment.Results: Overall therapeutic responses were 69.2% in Group A and 68.2% in group B. Side effects were noted in 65.4% patient of group A and 36.4% patient of group B. In group A, the commonest (38.5%) side effect was excessive weight gain with cushingoid facies and in group B, commonest (27.3%) side effect was ulceration at injection site. Side effects were more in children of group A. Range of treatment was 4-20 weeks in group A and in group B, it was 4-24 weeks.Conclusion: IL Dexamethasone is effective as oral Prednisolone for treatment of IH .Unlike Prednisolone, IL Dexamethasone is devoid of systemic side effects.J. Paediatr. Surg. Bangladesh 5(1): 12-19, 2014 (January)

Treatment of infantile haemoangioma – Update 2016

Phlebologie ◽  
2016 ◽  
Vol 45 (04) ◽  
pp. 194-200
Author(s):  
A. Mangatter ◽  
P. Ruef
Keyword(s):  
Side Effects ◽  
Topical Treatment ◽  
Systemic Treatment ◽  
Infantile Hemangioma ◽  
Serum Levels ◽  
Arterial Blood ◽  
Paediatric Patients ◽  
Propranolol Treatment ◽  
Insight Into ◽  
Systemic Drug

Summary Aim Complicated infantile hemangioma need early, safe and effective treatment. The aim of this study was to provide greater insight into systemic and topical propranolol treatment efficacy and side effects. Methods We report our retrospective experiences of 207 paediatric patients treated with systemic propranolol and of 148 paediatric patients treated with propranolol gel topically photographed and analysed with a specific hemangioma score. Results Propranolol treatment was successful in >99 % of the patients. The hemangioma score showed a significant decrease during systemic treatment (8.3 ± 3.3 at beginning and 1.5± 1.4 after 6 months) and during topical treatment (4.2 ± 1,6 at beginning and 2.2 ± 1.3 after three months). Systemic treatment did not show any differences when distributed according to different localizations or to the patient`s ages. During topical propranolol treatment relevant serum levels were not determined. Relevant side effects that may have made it necessary to discontinue the treatment were not observed. However, there was a statistically significant reduction in heart rate but not in mean arterial blood pressure during the first six in-hospital systemic drug applications. Conclusion Systemic propranolol treatment is highly effective and nearly always safe. Topical treatment with propranolol gel (off-label) is suitable for specific hemangioma in addition to cryotherapy and systemic treatment with propranolol. These findings provide highly valuable information on this drug treatment for complicated infantile hemangioma in infants.

scholarly journals Safety and Efficacy of Imiquimod in the Treatment of Infantile Hemangioma; a Systematic Review and Meta-Analysis

2020 ◽  
Vol 3 (03) ◽  
Author(s):  
Abdullah Alakeel
Keyword(s):  
Systematic Review ◽  
Side Effects ◽  
Therapeutic Agent ◽  
Meta Analysis ◽  
Infantile Hemangioma ◽  
Clinical Resolution ◽  
Safety And Efficacy ◽  
High Prevalence ◽  
Superficial Type ◽  
Local Side

Objective: To study the safety and efficacy of imiquimod in the treatment of infantile hemangioma (IH). Method: Systematic search was conducted in nine electronic databases for selecting relevant articles reporting the safety and efficacy of imiquimod as a therapeutic agent for treatment of IH. Meta-analysis was used to pool the results. Results: Of total 180 records screened, we included 9 studies for this systematic review and meta-analysis. About one-fifth of the patients (20.9%) have showed clinical resolution with 95% confidence interval (CI) of 11.8% to 34.1%. Regarding IH type, superficial type showed the highest rates of both clinical resolution and excellent response rates with 31.2% (95% CI= 16.6% to 50.8%) and 26.5% (95% CI= 11.6% to 49.6%), respectively. A relatively high prevalence of any side effects with 63.1% (95% CI= 47.6% to 76.3%) has been reported. The highest reported side effect was crustation (44.1%; 95% CI= 27.8% to 61.8%). Conclusion: Imiquimod is effective in the treatment of superficial IH and it is associated with local side effects.

Gastric Ulcers Produced by Cisplatin

1981 ◽  
Vol 39 ◽  
pp. 582-583
Author(s):  
S.K. Aggarwal ◽  
J. San Antonio
Keyword(s):  
Electron Microscopy ◽  
Single Dose ◽  
Side Effects ◽  
Antitumor Agent ◽  
Gastric Ulcers ◽  
Enzyme Cytochemistry ◽  
Intestinal Toxicity ◽  
Ovarian Cancers ◽  
Inner Surface

Cisplatin (cis-dichlorodiammineplatinum(II)) a potent antitumor agent is now available for the treatment of testicular and ovarian cancers. It is however, not free from its serious side effects including nephrotoxicity, gastro intestinal toxicity, myelosuppression, and ototoxicity. Here we now report that the drug produces peculiar bloating of the stomach in rats and induces acute ulceration.Wistar-derived rats weighing 200-250 g were administered cisplatin(9 mg/kg) ip as a single dose in 0.15 M NaCl. After 3 days the animals were sacrificed by decapitation. The stomachs were removed, the contents analyzed for pepsin and acidity. The inner surface was examined with a dissecting microscope after a moderate stretching for ulcers. Affected areas were fixed and processed for routine electron microscopy and enzyme cytochemistry.The drug treated animals kept on food and water consistently showed bloating and lesions (Fig. 1) with a frequency of 6-70 ulcers in the rumen section of the stomachs.

Effects of cisplatin treatment on the rat neurohypophysis

1986 ◽  
Vol 44 ◽  
pp. 122-123
Author(s):  
J.M. Fadool ◽  
P.J. Boyer ◽  
S.K. Aggarwal
Keyword(s):  
Side Effects ◽  
Urine Output ◽  
Morphological Changes ◽  
Limiting Factor ◽  
Antineoplastic Drugs

Cisplatin (CDDP) is currently one of the most valuable antineoplastic drugs available. However, it has severe toxic side effects of which nephrotoxicity is the major dose limiting factor in its use. It induces morphological changes in the kidney with hampered urine output. The present study is an effort to determine the influence of the drug on the neurohypophysis for any antidiuretic effects on the kidney.

Severe Drooling and Treatment With Botulinum Toxin

2012 ◽  
Vol 21 (1) ◽  
pp. 15-21
Author(s):  
Merete Bakke ◽  
Allan Bardow ◽  
Eigild Møller
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Health Risk ◽  
Flow Rate ◽  
Clinical Evidence ◽  
Acetylcholine Release ◽  
Psychosocial Problems ◽  
Rate Reduction ◽  
Local Inhibition ◽  
Surgical Treatments

Severe drooling is associated with discomfort and psychosocial problems and may constitute a health risk. A variety of different surgical and non-surgical treatments have been used to diminish drooling, some of them with little or uncertain effect and others more effective but irreversible or with side effects. Based on clinical evidence, injection with botulinum toxin (BTX) into the parotid and submandibular glands is a useful treatment option, because it is local, reversible, and with few side effects, although it has to be repeated. The mechanism of BTX is a local inhibition of acetylcholine release, which diminishes receptor-coupled secretion and results in a flow rate reduction of 25–50% for 2–7 months.

Sign in / Sign up

Export Citation Format

Share Document